Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center

Background: Basal cell carcinoma (BCC) is the most common type of skin cancer and can represent a therapeutic challenge in patients with locally advanced disease. Vismodegib is a hedgehog pathway inhibitor approved by the FDA for use in this type of tumor. We present a case series to describe our ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayén-Rodríguez, Angela, Linares-González, Laura, Llamas-Segura, Carlos, Almazán-Fernández, Francisco Manuel, Ruiz-Villaverde, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218270/
https://www.ncbi.nlm.nih.gov/pubmed/37239551
http://dx.doi.org/10.3390/ijerph20105824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218270/
https://www.ncbi.nlm.nih.gov/pubmed/37239551
http://dx.doi.org/10.3390/ijerph20105824

Ejemplares similares